Cyclodextrin based erythropoietin formulation

Details Cyclodextrin based erythropoietin formulation Cyclodextrin based erythropoietin formulation

1992-06-30

1994-12-27

Wityshyn, Michael G.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 21, 514 58, 514777, 514814, 530380, 530395, 530397, 536 46, 536103, A61K 3710, C08B 3716

Patent

active

053766326

ABSTRACT:
The present invention relates to a new pharmaceutical composition for parenteral and local administration comprising an aqueous solution of erythropoietin and a .beta.- or .gamma.-cyclodextrin hydroxyalkyl derivative. The invention also relates to novel lyophilized or spray-dried erythropoietin compositions comprising a .beta.- or .gamma.-cyclodextrin hydroxyalkyl derivative, to processes for preparing such aqueous, lyophilized or spray-dried compositions and to a method for simultaneously stabilizing erythropoietin in an aqueous solution and preventing it from being adsorbed to surfaces.

REFERENCES:
patent: 4806524 (1989-02-01), Kawaguchi et al.
patent: 4824938 (1989-04-01), Koyama et al.
patent: 5024998 (1991-06-01), Bodor
patent: 5068227 (1991-11-01), Weinshenker
Muller et al, Journal of Pharmaceutical Sciences, vol. 75, No. 6, pp. 571-572, Jun. 1986.

Affiliated with

Also associated with

Rating

Cyclodextrin based erythropoietin formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclodextrin based erythropoietin formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclodextrin based erythropoietin formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-919798